HLVX | HilleVax, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	1.8900 - 2.0100
52 Week Range	1.5500 - 20.22
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	392,275
Average Volume	200,085
Shares Outstanding	49,806,070
Market Cap	98,616,019
Sector	Healthcare
Industry	Biotechnology
IPO Date	2022-04-29

Valuation
Profitability
Growth
Health
P/E Ratio	-0.64
Forward P/E Ratio	N/A
EPS	-3.09
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	90
Country	USA
Website	HLVX

HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.

HLVX's peers: CNTA, STRO, PMVP, ELYM, MNOV, PHVS, PEPG, MOLN, GLUE, TRDA, VIGL, IPSC, EWTX, CCCC, MLYS, CGEM, PRDS, STTK, CSBR, NAMSW, OPT, PMN, COYA

*Chart delayed

Analyzing fundamentals for HLVX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see HLVX Fundamentals page.

Watching at HLVX technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on HLVX Technicals page.